Clinical Trials
11 trialsNCT07598110 2026-05-20
FT-RIC-HAPLO
Institut Paoli-Calmettes
Phase 2 Not yet recruiting
NCT06954987 2026-05-13
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
National Cancer Institute (NCI)
Phase 2 Not yet recruiting
NCT07583303 2026-05-13
BSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 Mutation
City of Hope Medical Center
Phase 1 Not yet recruiting
NCT07563920 2026-05-04
TBF-AML
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase NA Not yet recruiting
NCT07565220 2026-05-04
Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
University of Pittsburgh
Phase 1 Not yet recruiting
NCT05565105 2026-03-03
CD34+ Transplants for Leukemia and Lymphoma
Baptist Health South Florida
Phase 2 Not yet recruiting
NCT07157514 2025-09-10
Radioimmunotherapy Conditioning With 131I- Apamistamab for Allogeneic Transplant in Relapse/Refractory AML
Actinium Pharmaceuticals
Phase 2/3 Not yet recruiting
NCT07025824 2025-09-03
RELEVANT
Technische Universität Dresden
Phase 2 Not yet recruiting
NCT06613035 2024-09-25
Twice-per-weekSelinexor, 2 Days Melphalan
Institute of Hematology & Blood Diseases Hospital, China
Phase 3 Not yet recruiting
NCT06297772 2024-06-04
Compare the Efficacy and Safety of Dec-FB4 and FB4 as Conditioning Regimen for AML-MR
Ruijin Hospital
Phase 3 Not yet recruiting
NCT06385808 2024-04-26
Efficacy and Safety of MTBF Conditioning Regimen for Salvageable Allo-HSCT in the Treatment of R/R AML
First Affiliated Hospital Xi'an Jiaotong University
Phase NA Not yet recruiting